Jean-Baptiste Agnus appointed AGC Biologics Chief Business Officer

KUALA LUMPUR, Nov 2 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jean-Baptiste Agnus as the company’s Chief Business Officer (CBO).

In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams, according to a statement.

“Jean-Baptiste is an experienced leader who has spent his career helping to build successful biopharmaceutical companies,” said AGC Biologics Chief Executive Officer, Patricio Massera.

“We are excited to have him on our global leadership team as our new CBO. We look forward to leveraging his experience as we continue to innovate and realise the full potential of our development and manufacturing capabilities.”

Meanwhile, Agnus said: “I am very excited to be joining the AGC Biologics team. I believe this company has a great business model, vast capabilities and a talented global team, which uniquely positions it to be a leader in the CDMO space.”

Agnus brings over 20 years of experience in biopharmaceuticals and contract development and manufacturing. He joins AGC Biologics after three years with Ajinomoto Bio-Pharma Services, where he led the company’s strategic vision of its worldwide sales and marketing activities.

Prior to that, he worked for 13 years at Novasep, and held a number of business development leadership roles with increasing responsibility both in Europe and the US.

Agnus joins at a critical time for AGC Biologics, as the company has seen record-level growth over the last several years.

The company invested in expanding its services and capabilities in the cell and gene therapy space, and now has a network of sites on three continents that support the needs of biologics and cell and gene therapeutics developers.

More details at www.agcbio.com.

-- BERNAMA